Results 1 to 10 of about 46,095 (261)

Epidemiology of non-vaccine serotypes of Streptococcus pneumoniae before and after universal administration of pneumococcal conjugate vaccines

Human Vaccines & Immunotherapeutics, 2021
The universal administration of pneumococcal conjugate vaccines (PCVs) had been demonstrated as an effective way to prevent Streptococcus pneumoniae infection.
Qian-qian Du, Wei Shi, Dan Yu, Kai-hu Yao   +3 more
doaj   +2 more sources

Strengths and weaknesses of pneumococcal conjugate vaccines

Glycoconjugate Journal, 2023
AbstractMultivalent vaccines addressing an increasing number of Streptococcus pneumoniae types (7-, 10-, 13-, 15-, 20-valent) have been licensed over the last 22 years. The use of polysaccharide-protein conjugate vaccines has been pivotal in reducing the incidence of invasive pneumococcal disease despite the emergence of non-vaccine serotypes ...
Micoli, Francesca, Romano, Maria Rosaria, Carboni, Filippo, Adamo, Roberto, Berti, Francesco   +4 more
openaire   +3 more sources

Effect of pneumococcal conjugate vaccine six years post-introduction on pneumococcal carriage in Ulaanbaatar, Mongolia [PDF]

Nature Communications
Limited data from Asia are available on long-term effects of pneumococcal conjugate vaccine introduction on pneumococcal carriage. Here we assess the impact of 13-valent pneumococcal conjugate vaccine (PCV13) introduction on nasopharyngeal pneumococcal ...
Claire von Mollendorf, Tuya Mungun, Munkhchuluun Ulziibayar, Paige Skoko, Laura Boelsen, Cattram Nguyen, Purevsuren Batsaikhan, Bujinlkham Suuri, Dashtseren Luvsantseren, Dorj Narangerel, Bilegtsaikhan Tsolmon, Sodbayar Demberelsuren, Belinda D. Ortika, Casey L. Pell, Ashleigh Wee-Hee, Monica L. Nation, Jason Hinds, Eileen M. Dunne, E. Kim Mulholland, Catherine Satzke   +19 more
doaj   +2 more sources

Development of a pneumococcal conjugate vaccine [PDF]

Paediatrics & Child Health, 2001
George R. Siber
openalex   +3 more sources

Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2022

MMWR. Morbidity and mortality weekly report, 2022
In 2021, 20-valent pneumococcal conjugate vaccine (PCV) (PCV20) (Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.) and 15-valent PCV (PCV15) (Merck Sharp & Dohme Corp.) were licensed by the Food and Drug Administration for adults aged ≥18 years ...
Miwako Kobayashi, Jennifer L. Farrar, R. Gierke, Amadea Britton, L. Childs, A. Leidner, D. Campos-Outcalt, Rebecca L Morgan, Sarah S. Long, H. Talbot, K. Poehling, T. Pilishvili   +11 more
semanticscholar   +1 more source

Use of 15-Valent Pneumococcal Conjugate Vaccine Among U.S. Children: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2022

MMWR. Morbidity and mortality weekly report, 2022
The 13-valent pneumococcal conjugate vaccine (PCV13 [Prevnar 13, Wyeth Pharmaceuticals, Inc, a subsidiary of Pfizer, Inc]) and the 23-valent pneumococcal polysaccharide vaccine (PPSV23 [Merck Sharp & Dohme LLC]) have been recommended for U.S.
Miwako Kobayashi, Jennifer L. Farrar, R. Gierke, A. Leidner, D. Campos-Outcalt, Rebecca L Morgan, S. Long, K. Poehling, A. Cohen, K. Poehling, S. Long, J. Kelman, Lucia Lee, Tina Mongeau, T. Weiser, Uzo Chukwuma, Kristina Lu, M. Makhene, Lynn Fisher, Mark Sawyer, Jason Goldman, D. Nace, Emily Messerli, Elissa Abrams, Aleksandra K. Wierzbowski, Carol Baker, James McAuley, W. Schaffner, Virginia Cane, D. Campos-Outcalt, M. Farley, K. Klugman, Rebecca L Morgan, A. Reingold, L. Rubin, C. Whitney, R. Zimmerman, Emma K. Accorsi, Alison P. Albert, Shriya Bhatnagar, L. Childs, M. Fischer, R. Gorwitz, Angela J. Jiles, Heidi L Moline, P. Moro, Chukwuebuka Nsofor, N. Prasad, H. Walker, Jacquline Risalvato, S. Schillie   +50 more
semanticscholar   +1 more source

Incidence and Estimated Vaccine Effectiveness Against Hospitalizations for All-Cause Pneumonia Among Older US Adults Who Were Vaccinated and Not Vaccinated With 13-Valent Pneumococcal Conjugate Vaccine

JAMA Network Open, 2022
This cohort study estimates the association between vaccination with 13-valent pneumococcal conjugate vaccine and hospitalizations for all-cause pneumonia and lower respiratory tract infection among older adults in a large health care system in ...
Amber Hsiao, John Hansen, Julius Timbol, N. Lewis, R. Isturiz, Ronika Alexander-Parrish, John M. McLaughlin, Bradford D. Gessner, Nicola P. Klein   +8 more
semanticscholar   +1 more source

Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged ≥18 Years

Clinical Infectious Diseases, 2021
Background Pneumococcal conjugate vaccines (PCVs) have significantly reduced pneumococcal disease, but disease from non-PCV serotypes remains. The safety, tolerability, and immunogenicity of a 20-valent PCV (PCV20) were evaluated.
B. Essink, Charu Sabharwal, Kevin P. Cannon, R. Frenck, Himal Lal, Xia Xu, V. Sundaraiyer, Yahong Peng, Lisa Moyer, M. Pride, Ingrid L Scully, K. Jansen, W. Gruber, D. Scott, W. Watson   +14 more
semanticscholar   +1 more source

Cost‐effectiveness of second‐line therapies in adults with chronic immune thrombocytopenia

American Journal of Hematology, Volume 98, Issue 1, Page 122-130, January 2023., 2023
Abstract Major options for second‐line therapy in adults with chronic immune thrombocytopenia (ITP) include splenectomy, rituximab, and thrombopoietin receptor agonists (TRAs). The American Society of Hematology guidelines recommend rituximab over splenectomy, TRAs over rituximab, and splenectomy or TRAs while noting a lack of evidence on the cost ...
George Goshua, Pranay Sinha, Natalia Kunst, Lauren Pischel, Alfred Ian Lee, Adam Cuker   +5 more
wiley   +1 more source

COVID‐19 and myasthenia gravis: A review of neurological implications of the SARS‐COV‐2

Brain and Behavior, Volume 12, Issue 12, December 2022., 2022
Abstract Introduction This review highlights the potential mechanisms of neuromuscular manifestation of COVID‐19, especially myasthenia gravis (MG). Methods An extensive literature search was conducted by two independent investigators using PubMed/MEDLINE and Google Scholar from its inception to December 2020. Results Exacerbations of clinical symptoms
Syed Muhammad Ismail Shah, Farah Yasmin, Roha Saeed Memon, Nadia Nazir Jatoi, Ilma Saleh Savul, Sana Kazmi, Syed Abdullah Monawwer, Muhammad Daim Bin Zafar, Muhammad Sohaib Asghar, Muhammad Junaid Tahir, Ka Yiu Lee   +10 more
wiley   +1 more source